Analysts Set aTyr Pharma, Inc. (NASDAQ:ATYR) PT at $20.20

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.20.

Several research firms recently weighed in on ATYR. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Wells Fargo & Company raised their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, June 20th.

Hedge Funds Weigh In On aTyr Pharma

Several institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. bought a new position in aTyr Pharma during the fourth quarter valued at $53,093,000. Point72 Asset Management L.P. bought a new position in aTyr Pharma during the fourth quarter valued at $17,677,000. Octagon Capital Advisors LP lifted its position in aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company’s stock valued at $10,727,000 after purchasing an additional 2,652,000 shares during the last quarter. Tikvah Management LLC bought a new position in aTyr Pharma during the fourth quarter valued at $8,908,000. Finally, Woodline Partners LP bought a new position in aTyr Pharma during the fourth quarter valued at $6,092,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Stock Performance

Shares of NASDAQ ATYR opened at $5.11 on Monday. The firm has a fifty day moving average price of $4.12 and a 200-day moving average price of $3.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. The stock has a market cap of $454.79 million, a PE ratio of -6.31 and a beta of 0.88. aTyr Pharma has a 1 year low of $1.47 and a 1 year high of $5.98.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. Equities analysts anticipate that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.